GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy skidded.

The post GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations appeared first on Investor’s Business Daily.